Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22157388 | 0.95 | TSHR (0.65) | TSHRALDH1A1DNM1FAAH | |
| SCHEMBL22157379 | 0.95 | TSHR (0.65) | TSHRALDH1A1DNM1FAAH | |
| SCHEMBL17398951 | 0.95 | TSHR (0.65) | TSHRALDH1A1DNM1 | |
| SCHEMBL7783171 | 0.95 | TSHR (0.73) | TSHRALDH1A1DNM1FAAHTRPV1 | |
| SCHEMBL18701402 | 0.95 | TSHR (0.65) | TSHRALDH1A1DNM1 | |
| SCHEMBL22157441 | 0.93 | TSHR (0.62) | TSHRALDH1A1DNM1FAAH | |
| SCHEMBL15951725 | 0.93 | TSHR (0.61) | TSHRALDH1A1DNM1 | |
| SCHEMBL22157404 | 0.93 | TSHR (0.61) | TSHRALDH1A1DNM1FAAH | |
| SCHEMBL18780475 | 0.91 | TSHR (0.60) | TSHRALDH1A1DNM1 | |
| SCHEMBL22157536 | 0.91 | TSHR (0.60) | TSHRALDH1A1DNM1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| EP-3854303-A1 | BIO-ELECTRODE COMPOSITION, BIO-ELECTRODE, AND METHOD FOR MANUFACTURING BIO-ELECTRODE | Shin-Etsu Chemical Co., Ltd. (JP) | 2021-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | IL2, IL4, PBK | TSHR 3328/4885ALDH1A1 1785/4885DNM1 3675/4885 |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | IL2, PBK, IL4 | TSHR 3553/4885ALDH1A1 1217/4885DNM1 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.